Alzheimer’s disease is characterised by very highlevels of a molecule called beta-amyloid in the brain. PiB PET can show the beta-amyloid in the brain. AIBL researchers have shown that this scan can be used as a diagnostic tool to potentially distinguish patients with early Alzheimer’s disease from others without the disease, even before clear signs of memory loss are present.
Dementia, most of which is caused by Alzheimer’s disease, affects over 200 000 Australians, with the number expected to rise to over 700 000 by 2050. Alzheimer’s was estimated to have cost $5.6 billion in 2002. Delaying the onset of Alzheimer’s disease by just five years has been calculated to reduce new cases by 50 per cent, with cumulative Australian health cost sa
Photographer : Nick Pitsas on June 04 2008.
To embed this image on your own website, please copy and paste the following code.
<table style="border:1px solid;padding:2px; width:310px;" ><tr><td><a href="https://www.scienceimage.csiro.au/image/9370/"><img src="https://www.scienceimage.csiro.au/images/embed/300_0_PH9631.jpg" width="300" alt="Amyloid beta plaque in the brain follows specific patterns as detected by CSIRO’s analysis technique from PiB PET scans – here an AIBL volunteer is receiving a PiB PET scan" style="margin: 0 0 5px 0; border: 0px;"></a><br/><a href="https://www.scienceimage.csiro.au/image/9370/">Amyloid beta plaque in the brain follows specific patterns as detected by CSIRO’s analysis technique from PiB PET scans – here an AIBL volunteer is receiving a PiB PET scan</a><br />by CSIRO</td></tr></table>
![]() Amyloid beta plaque in the brain follows specific patterns as detected by CSIRO’s analysis technique from PiB PET scans – here an AIBL volunteer is receiving a PiB PET scan by CSIRO |
By downloading this image, you agree to abide by the following terms.
Attribution - You must give the original author credit.